National Lipid Association Annual Summary of Clinical Lipidology 2015

被引:63
作者
Bays, Harold E. [1 ]
Jones, Peter H. [2 ]
Brown, W. Virgil [3 ]
Jacobson, Terry A. [4 ]
机构
[1] Louisville Metab & Atherosclerosis Res Ctr, Louisville, KY 40213 USA
[2] Baylor Coll Med, Houston, TX 77030 USA
[3] Emory Univ, Sch Med, Atlanta, GA USA
[4] Emory Univ, Dept Med, Atlanta, GA 30322 USA
关键词
Clinical Lipidology; Dyslipidemia; National Lipid Association; Annual Summary; Cholesterol; Recommendations; Guidelines; CORONARY-HEART-DISEASE; HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; DENSITY-LIPOPROTEIN CHOLESTEROL; SUBTILISIN/KEXIN TYPE 9; EVALUATING ROSUVASTATIN JUPITER; CARDIOVASCULAR RISK-FACTORS; POLYCYSTIC-OVARY-SYNDROME; TASK-FORCE; EXPERT PANEL; MYOCARDIAL-INFARCTION;
D O I
10.1016/j.jacl.2014.10.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The National Lipid Association (NLA) Annual Summary of Clinical Lipidology 2015 is a summary of principles important to the patient-centered evaluation, management, and care of patients with dyslipidemia. This summary is intended to be a "living document," with future annual updates based on emerging science, clinical considerations, and new NLA Position and Consensus Statements. The goal is to provide clinicians an ongoing resource that translates the latest advances in medical science toward the evaluation and treatment of patients with dyslipidemia. The 2015 NLA Annual Summary of Clinical Lipidology was founded on the principles of evidence-based medicine and is generally consistent with established national and international lipid guidelines. Topics include a general discussion of the 2014 NLA Recommendations for Patient-Centered Management of Dyslipidemia, genetics, secondary causes of dyslipidemia, biomarkers and "advanced lipid testing," medical nutrition, physical activity, obesity, pharmacotherapy, statin safety, lipid-altering drug interactions, lipoprotein apheresis, dyslipidemia in children and adolescence, dyslipidemia in older individuals, race/ethnicity, and women, health information technology and electronic medical records, as well as investigational lipid-altering drugs in development. (C) 2014 National Lipid Association. All rights reserved.
引用
收藏
页码:S1 / S36
页数:36
相关论文
共 157 条
  • [1] Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial
    Albert, Michelle A.
    Glynn, Robert J.
    Fonseca, Francisco A. H.
    Lorenzatti, Alberto J.
    Ferdinand, Keith C.
    MacFadyen, Jean G.
    Ridker, Paul M.
    [J]. AMERICAN HEART JOURNAL, 2011, 162 (01) : 106 - U147
  • [2] Effects of conjugated, equine estrogen in postmenopausal women with hysterectomy - The women's health initiative randomized controlled trial
    Anderson, GL
    Limacher, M
    Assaf, AR
    Bassford, T
    Beresford, SAA
    Black, H
    Bonds, D
    Brunner, R
    Brzyski, R
    Caan, B
    Chlebowski, R
    Curb, D
    Gass, M
    Hays, J
    Heiss, G
    Hendrix, S
    Howard, BV
    Hsia, J
    Hubbell, A
    Jackson, R
    Johnson, KC
    Judd, H
    Kotchen, JM
    Kuller, L
    LaCroix, AZ
    Lane, D
    Langer, RD
    Lasser, N
    Lewis, CE
    Manson, J
    Margolis, K
    Ockene, J
    O'Sullivan, MJ
    Phillips, L
    Prentice, RL
    Ritenbaugh, C
    Robbins, J
    Rossouw, JE
    Sarto, G
    Stefanick, ML
    Van Horn, L
    Wactawski-Wende, J
    Wallace, R
    Wassertheil-Smoller, S
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (14): : 1701 - 1712
  • [3] 2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult
    Anderson, Todd J.
    Gregoire, Jean
    Hegele, Robert A.
    Couture, Patrick
    Mancini, G. B. John
    McPherson, Ruth
    Francis, Gordon A.
    Poirier, Paul
    Lau, David C.
    Grover, Steven
    Genest, Jacques, Jr.
    Carpentier, Andre C.
    Dufour, Robert
    Gupta, Milan
    Ward, Richard
    Leiter, Lawrence A.
    Lonn, Eva
    Ng, Dominic S.
    Pearson, Glen J.
    Yates, Gillian M.
    Stone, James A.
    Ur, Ehud
    [J]. CANADIAN JOURNAL OF CARDIOLOGY, 2013, 29 (02) : 151 - 167
  • [4] [Anonymous], J CARDIOPULM REHABIL, DOI DOI 10.1097/00008483-200605000-00002
  • [5] [Anonymous], J CARDIOPULM REHABIL
  • [6] Hypercholesterolemia and coronary heart disease in the elderly: A meta-analysis
    Anum, EA
    Adera, T
    [J]. ANNALS OF EPIDEMIOLOGY, 2004, 14 (09) : 705 - 721
  • [7] Apovian CM, 2014, PHARM MANAG IN PRESS
  • [8] Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Munster (PROCAM) study
    Assmann, G.
    Schulte, H.
    Cullen, P.
    Seedorf, U.
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2007, 37 (12) : 925 - 932
  • [9] Do we need to consider inflammatory markers when we treat atherosclerotic disease?
    Athyros, Vasilios G.
    Kakafika, Anna I.
    Karagiannis, Asterios
    Mikhailidis, Dimitri P.
    [J]. ATHEROSCLEROSIS, 2008, 200 (01) : 1 - 12
  • [10] Genetic causes of monogenic heterozygous familial hypercholesterolemia: A HuGE prevalence review
    Austin, MA
    Hutter, CM
    Zimmern, RL
    Humphries, SE
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 2004, 160 (05) : 407 - 420